EGFR and colorectal carcinoma: Another study [87], Bertotti et al., took a similar screening approach, in this case using over 100 different colorectal cancer (CRC) models (n = 5 or 6) to profile the efficacy of epidermal growth factor receptor (EGFR) inhibitor, cetuximab, and found concordance in the response to this drug to EGFR-amplified models and CRC patients in the clinic.